 | This article needs additional citations for verification. (May 2018) |
 | |
| Company type | Public limited company |
|---|---|
| Nasdaq Stockholm: MVIR B | |
| Industry | Biotechnology |
| Founded | 1988 |
| Headquarters | Huddinge, Sweden |
Area served | Global |
Key people | Uli Hacksell (CEO) |
| Products | Oncological R&D |
| Revenue | 658 MM SEK (2015) |
Number of employees | 15 |
| Website | www.medivir.com |
Medivir is a Swedish biotech company.[1] Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.[2] Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China.[3]
- ^ "Swedish pharma firm Medivir partners Aragen Life Sciences for drug research". The Economic Times. 16 July 2015. Retrieved 1 December 2016.
- ^ "Medivir website". Medivir. 1 June 2015. Retrieved 13 December 2016.
- ^ "Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear® in China". BioSpace. Retrieved 2020-02-25.